SEARCH

SEARCH BY CITATION

References

  • 1
    Holmes SC, Bankowska U, Mackie RM. The prescription of isotretinoin to women: is every precaution taken? Br J Dermatol 1998; 138: 4505.
  • 2
    Azoulay L, Oraichi D, Bérard A. Patterns and utilization of isotretinoin from 1984 to 2003: is there need for concern? Eur J Clin Pharmacol 2006; 62: 66774.
  • 3
    Moskop JC, Smith ML, De Ville K. Ethical aspects of teratogenic medications: the case of isotretinoin. J Clin Ethics 1997; 8: 26478.
  • 4
    Honein MA, Paulozzi LJ, Erickson JD. Continued occurrence of Accutanemd – exposed pregnancies. Teratology 2001; 64: 1427.
  • 5
    Mitchell AA, Van Bennekom CM, Louik C. A pregnancy-prevention program in women of childbearing age receiving isotretinoin. N Engl J Med 1995; 333: 1016.
  • 6
    Pastuszak A, Koren G, Rieder MJ. Use of the Retinoid Pregnancy Prevention Program in Canada: patterns of contraception use in women treated with isotretinoin and etretinate. Reprod Toxicol 1994; 8: 638.
  • 7
    Atanackovic G, Koren G. Fetal exposure to oral isotretinoin: failure to comply with the Pregnancy Prevention Program. CMAJ 1999; 160: 17198.
  • 8
    Dai WS, LaBraico JM, Stern RS. Epidemiology of isotretinoin exposure during pregnancy. J Am Acad Dermatol 1992; 26: 599606.
  • 9
    Rosa FW. Teratogenicity of isotretinoin. Lancet 1983; 2: 513.
  • 10
    Dermatologic and Opthalmic Drugs Advisory Committee. Briefing Information. 1819 September 2000. Available at http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3639b1.htm (last accessed: 15 December 2004).
  • 11
    Jones KL, Adams J, Chambers CD, Erickson JD, Lammer E, Polifka J. Isotretinoin and pregnancy. JAMA 2001; 285: 10225.
  • 12
    World Health Organization. International Classification of Diseases, 9th Revision (ICD-9). Geneva: World Health Organization 1977.
  • 13
    Tamblyn R, Lavoie G, Petrella L, Monette J. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 1995; 48: 9991009.
  • 14
    Physicians Desk Reference. Product Labeling for Isotretinoin. Montvale, NJ: Medical Economics Company, Inc. 2001.
  • 15
    Statistical Analysis Software Institute Inc. Version 8.2. Cary, NC: SAS Inc, 2001.
  • 16
    Abrishamchian AR, Khoury MJ, Calle EE. The contribution of maternal epilepsy and its treatment to the etiology of oral clefts: a population based case–control study. Genet Epidemiol 1994; 11: 34351.
  • 17
    Demissie K, Breckenridge MB, Rhoads GG. Infant and maternal outcomes in the pregnancies of asthmatic women. Am J Respir Crit Care Med 1998;158: 10915.
  • 18
    Kallen B, Tandberg A. Lithium and pregnancy. A cohort study on manic-depressive women. Acta Psychiatr Scand 1983; 68: 1349.
  • 19
    Rosa FW. Spina bifida in infants of women treated with carbamazepine during pregnancy. N Engl J Med 1991; 324: 6747.
  • 20
    Samren EB, Van Duijn CM, Christiaens GC, Hofman A, Lindhout D. Antiepileptic drug regimens and major congenital abnormalities in the offspring. Ann Neurol 1999; 46: 73946.
  • 21
    Sorensen HT, Nielsen GL, Olesen C, Larsen H, Steffensen FH, Schonheyder HC, Olsen J, Czeizel AE. Risk of malformations and other outcomes in children exposed to fluconazole in utero. Br J Clin Pharmacol 1999; 48: 2348.
  • 22
    Thulstrup AM, Sorensen HT, Nielsen GL, Andersen L, Barrett D, Vilstrup H, Olsen J. EuroMap Study Group. Fetal growth and adverse birth outcomes in women receiving prescriptions for acetaminophen during pregnancy. Am J Perinatol 1999; 16: 3216.
  • 23
    West R, Sherman GJ, Downey W. A record linkage study of valproate and malformations in Saskatchewan. Can J Public Health 1985; 76: 2268.
  • 24
    Garbe E, LeLorier J, Boivin JF, Suissa S. Risk of ocular hypertension or open-angle glaucoma in elderly patients on oral glucocorticoids. Lancet 1997; 350: 97982.
  • 25
    Garbe E, LeLorier J, Boivin JF, Suissa S. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma. JAMA 1997; 277: 7227.
  • 26
    Blais L, Desgagne A, LeLorier J. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case–control study. Arch Intern Med 2000; 160: 23638.
  • 27
    Robertson JA, Martinez LP, Gallegos S, Leen-Mitchell MJ, Garcia V, Neuman J, Carey JC. Accutane cases: a teratogen information service's approach. Teratology 2002; 66: 12.